Lineage Cell Therapeutics, Inc. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2021-03-31 was $202.00K.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2020-09-30 was $119.00K.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2014-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2021 was $202.00K, a 69.75% increase from fiscal 2020.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2020 was $119.00K.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2017 was $3.00K, a 92.50% decline from fiscal 2016.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2016 was $40.00K.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2021-12-31 | $202.00K 10-K · filed 2023-03-09 | |
| 2021-03-31 | $202.00K 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $119.00K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $119.00K 10-Q · filed 2021-11-10 | |
| 2017-12-31 | $3.00K 10-K · filed 2019-03-14 | |
| 2016-12-31 | $40.00K 10-K · filed 2018-03-15 | |
| 2015-12-31 | $0.00 10-K · filed 2016-03-15 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $0.00 10-K · filed 2016-03-15 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$100.00 derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $24.08K derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-12 | $95.72K derived: sum of 4 quarters · filed 2016-03-15 |
| 2013-12-31 | -$100.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $173.00K 10-K · filed 2016-03-15 |
| 2013-09-30 | $24.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $173.10K derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-06-30 | $71.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $148.92K derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-03-31 | $77.28K 10-Q · filed 2014-05-12 | $77.28K derived: sum of 4 quarters · filed 2015-03-11 |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $0.00 10-K · filed 2015-03-11 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | |
| 2012-03-31 | $0.00 10-Q · filed 2013-05-10 | |
| 2011-12-31 | $0.00 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |